



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-U74899UR2001PLC033407

Ref No. WBL/SE/2021-2022

September 8, 2021

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Dear Sir/ Madam.

Please find attached herewith press release on Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021.

Kindly take the same on record.

Thanking you,

Yours faithfully,

Ananta Narayan Panda



Windlas Biotech Limited Reports its Q1FY22 Financial Results



- ✓ **Successfully concludes the IPO with ~22.4x**

Windlas Biotech Limited, one of the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, reported its unaudited financials for the quarter ended June 30, 2021.

- Revenue from operations stood at Rs. 111.0 crores as against Rs. 102.3 crores, a growth of 8.5% YoY, however considering the impact of shift in revenue of Rs. 7 crores from Q4FY20 to Q1FY21, the revenue growth would be 16.5% YoY .
- stood at Rs. 12.8 crores as against Rs. 13.7 crores YoY. came in at 11.5%.
- stood at Rs. 6.7 crores as against Rs. 5.3 crores, up 26.4% YoY.

CDMO	95.7	87.8	9%	87.1	10%
Trade Generics	12.3	9.0	37%	11.3	9%
Exports	2.2	5.3	(58)%	8.3	(73)%

- Q1 revenue for the CDMO segment stood at Rs. 95.7 crores, up 9% YoY, led to a pick-up in Covid-19 related therapies.
- CDMO segment contributed approximately 86% to the consolidated revenue.
- Q1 revenue for the Trade Generics segment stood at Rs. 12.3 crores, up 37% YoY.
- Trade Generics segment contributed approximately 11% to the consolidated revenue.
- Q1 revenue for the Exports segment stood at Rs. 2.2 crores, down 58% YoY, mainly on account of disruptions in the supply chain.

- The exports segment contributed approximately 2% to the consolidated revenue.

Commenting on the results Mr. Hitesh Windlass, Managing Director – Windlas Biotech said, “

I would also like to thank customers, suppliers, employees and all other vendors and stakeholders for their valued support and service.

”

Adding further, Ms. Komal Gupta, CFO - Windlas Biotech said “

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.



CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: Komal@windlasbiotech.com

Contact no.: +91 124 2821034



CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar

Email: jigar.kavaiya@sgapl.net / chinmay.m@sgapl.net

Contact no.: +91 9920602034 / +91 9860088296